此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)

2026年5月24日 更新者:Wen-zhao ZHONG

Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer

The SCIENCE trial is a multicenter, open-label, randomized, parallel, noninferiority investigator-initiated trial (IIT). This study aims to evaluate the prognostic differences between selective mediastinal lymph node sampling and systematic mediastinal lymph node dissection in patients with node-negative stage IIA to IIIB (N2) non-small-cell lung cancer (NSCLC) undergoing anatomical lobectomy following neoadjuvant chemoimmunotherapy.

研究概览

研究类型

介入性

注册 (估计的)

358

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510080
        • Guangdong Provincial People's Hospital
        • 接触:
        • 首席研究员:
          • Wen-Zhao Zhong, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Voluntary participation with a signed written informed consent form.
  2. Aged ≥ 18 and < 75 years, of either gender.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  4. Anticipated life expectancy of ≥ 12 months.
  5. Histologically or pathologically confirmed peripheral non-small cell lung cancer (NSCLC), with clinical tumor, node, metastasis(TNM) stage IIA-IIIB, which according to the International Association for the Study of Lung Cancer(IASLC) 9th edition, and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
  6. Absence of satellite nodules involving different lung lobes.
  7. No history of prior ipsilateral thoracotomy.
  8. Completion of neoadjuvant therapy prior to enrollment, consisting of a PD-1 inhibitor combined with platinum-based doublet chemotherapy.
  9. Adequate organ function.
  10. Cardiopulmonary function assessed by the investigator as meeting surgical standards, specifically: forced expiratory volume in one second (FEV1) > 1.0 L or diffusing capacity of the lung for carbon monoxide (DLCO) > 40% of the predicted value; and no other cardiopulmonary impairments that, in the investigator's judgment, would preclude surgery.
  11. Evaluation by a multidisciplinary team (MDT) or an evaluation committee* confirming that R0 resection can be achieved via anatomical lobectomy.

    • Evaluation Committee: Composed of multidisciplinary experts with at least 10 years of clinical experience. Each participant's eligibility is discussed and evaluated by at least two experts to reach a consensus; in the event of a disagreement, a third expert will be invited for assessment.

Exclusion Criteria:

  1. Anticipated inability to tolerate an anatomical lobectomy;
  2. Anticipated requirement for sleeve resection, pneumonectomy, or pulmonary autotransplantation to remove the affected lobe;
  3. Prior thoracic radiotherapy before the initiation of surgical treatment;
  4. History of allogeneic tissue or solid organ transplantation;
  5. Diagnosis of an autoimmune disease within 3 months prior to surgery, or currently receiving long-term systemic corticosteroid therapy (at a dose >10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy;
  6. History of or current non-infectious interstitial lung disease requiring corticosteroid therapy;
  7. Presence of viral infectious diseases during the screening period:

    1. Seropositivity for human immunodeficiency virus (HIV);
    2. Active hepatitis B: positive for hepatitis B surface antigen (HBsAg) with an HBV-DNA viral load >500 IU/mL or >2000 copies/mL;
    3. Active hepatitis C: positive for hepatitis C virus (HCV) antibody with an HCV-RNA viral load above the upper limit of normal (ULN);
  8. Poorly controlled hypertension despite medical therapy, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg (adjustment of antihypertensive medications is permitted prior to study initiation, provided that the average of the last three consecutive blood pressure readings taken prior to enrollment is ≤150/90 mmHg, with at least a 2-minute interval between each measurement);
  9. Active infection requiring intravenous anti-infective therapy at the time of screening;
  10. History of another malignancy within 3 years prior to providing informed consent, excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix or breast, superficial bladder cancer, and localized prostate cancer. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, PSA <10 ng/mL) are eligible to enroll if they have received radical treatment or are under active surveillance with stable disease, regardless of prior treatment status;
  11. Any condition that, in the investigator's judgment, might interfere with the interpretation of study results, compromise the participant's ability to complete the study, or render study participation contrary to the participant's best interests;
  12. Pregnant, lactating, or planning to become pregnant; or having a positive serum pregnancy test within 7 days prior to the first study treatment;
  13. Poor compliance, or unwilling or unable to adhere to the protocol-specified procedures.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:selective mediastinal lymph node sampling group
Patients randomized to the investigational group will undergo an anatomical lobectomy. Subsequently, no further lymph node resection or dissection will be performed in regional stations confirmed negative for metastasis by preoperative or intraoperative pathological evaluation (including negative preoperative endobronchial ultrasound [EBUS]-guided biopsies and negative intraoperative frozen sections). Postoperatively, patients will receive 1 cycle of platinum-based doublet chemotherapy combined with toripalimab immunotherapy, followed by 13 cycles of toripalimab immunotherapy.
有源比较器:systematic medIastinal lymph node dissection group
Patients randomized to the control group will undergo a systematic mediastinal lymph node dissection following the completion of an anatomical lobectomy. A radical dissection and clearance of the mediastinal lymph nodes will be performed. For right-sided procedures, this encompasses the right upper paratracheal, right lower paratracheal, and subcarinal regions; for left-sided procedures, this encompasses the para-aortic, aortopulmonary window, left lower paratracheal, and subcarinal regions. Postoperatively, patients will receive 1 cycle of platinum-based doublet chemotherapy combined with toripalimab immunotherapy, followed by 13 cycles of toripalimab immunotherapy.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
2-year event-free survival (EFS) rate
大体时间:Up to 2 years
Up to 2 years

次要结果测量

结果测量
措施说明
大体时间
Intraoperative blood loss
大体时间:Intraoperative
Intraoperative
2-year disease-free survival (DFS) rate
大体时间:Up to 2 years
Up to 2 years
2-year overall survival (OS) rate
大体时间:Up to 2 years
Up to 2 years
Dynamic changes in absolute and relative peripheral blood lymphocyte counts
大体时间:Up to 2 years
Up to 2 years
Length of hospital stay
大体时间:Up to 30 days post-operation
Up to 30 days post-operation
time of operation
大体时间:Intraoperative
Intraoperative
postoperative recurrence rate (including the incidence of local recurrence and distant metastasis).
大体时间:Up to 2 years
Up to 2 years
Quality of life (QoL) scores at 6, 12, and 36 months postoperatively (assessed via the EORTC QLQ-C30).
大体时间:6, 12, and 24 months post-operation

Scale Title: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).

Minimum and Maximum Values: 0 to 5. Score Interpretation: The EORTC QLG Core Questionnaire (EORTC QLQ-C30) is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients. The EORTC QLQ-C30 consists of global health status, functional scales, and symptom scales. For the global health status and functional scales, higher scores represent a better quality of life/higher level of functioning. For the symptom scales, higher scores represent a higher level of symptomatology/worse outcome.

6, 12, and 24 months post-operation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月20日

初级完成 (估计的)

2030年5月15日

研究完成 (估计的)

2030年6月1日

研究注册日期

首次提交

2026年5月15日

首先提交符合 QC 标准的

2026年5月24日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月24日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅